Genitourinary Cancers Symposium 2013
ChemotherapyAdvisor.com Editorial Board Recommends High-Impact Abstracts from the 2013 Genitourinary Cancers Symposium
Dr. Neal Shore, MD, FACS, of Atlantic Urology Clinics shares his list of recommended abstracts that will be presented at the 2013 Genitourinary Cancers Symposium.
Survival rates rise as newer agents are used in combination therapies for patients with advanced prostate cancer.
Use of finasteride reduces the risk of a prostate cancer diagnosis, but does not significantly affect mortality rates after following men for 18 years, according to a study presented at the 2013 Genitourinary Cancers Symposium.
Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of mCRPC, according to research presented at the 2013 Genitourinary Cancers Symposium.
A urine-based assay "can markedly improve the accuracy" of detecting bladder cancer noninvasively, according to a case-controlled validation study reported during the 2013 Genitourinary Cancers Symposium.
No significant difference in overall survival was found between tivozanib and sorafenib in patients with advanced renal cell carcinoma, according to research presented at the 2013 Genitourinary Cancers Symposium.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- The Role of Microbes in Oncogenesis and the Treatment of Cancer
- The Undetermined Role of Sunscreen in Skin Cancer Prevention
- Lartruvo (Olaratumab) Offers New Promise for Patients With Soft Tissue Sarcoma
- Veliparib + Chemo Fails to Improve OS, PFS in Untreated NSCLC
- Regorafenib Improves PFS in Non-apidocytic Soft Tissue Sarcoma